BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 25
• 26
• 27
• 28
• 29

• Genetown

  New Data Suggesting Positive Effects of Sanofi Genzyme’s Lemtrada (Alemtuzumab) On Brain Volume Loss And Retinal Nerve Fibers To Be Presented At American Academy of Neurology

  April 18, 2016

   · 

  1 min read
• Drug Development

  Enanta Pharmaceuticals, Inc. Announces New Data From AbbVie’s SURVEYOR-1 And SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates After 8 Or 12 Weeks Of Treatment In Patients With Any Of Genotypes 1 Through 6 Of Hepatitis C Virus

  April 18, 2016

   · 

  8 min read
• Biotech Beach

  Ignyta Reports Granting Of Inducement Awards

  April 18, 2016

   · 

  2 min read
• Drug Development

  Merck & Co. Announces Results From Phase 3 Studies Of ZEPATIER (Elbasvir And Grazoprevir) In Chronic Hepatitis C Patient Populations At The International Liver Congress

  April 18, 2016

   · 

  13 min read
• Drug Development

  Nordic Nanovector: Betalutin Continues To Show Promising Efficacy And Increasing Duration Of Response (DoR)

  April 18, 2016

   · 

  6 min read
• BioMidwest

  Materion Precision Optics To Support World’s Largest Astronomical Filters

  April 18, 2016

   · 

  2 min read
• Business

  Ginkgo BioWorks Hires Peter Boynton As Chief Commercialization Officer To Expand Into Commodity Chemicals

  April 18, 2016

   · 

  1 min read
• Drug Development

  Multiple Myeloma Phase II Study Of BioInvent’s Antibody BI-505 Ready To Start

  April 18, 2016

   · 

  4 min read
• NeuroVive: Large Shareholder To Participate In The Rights Issue

  April 18, 2016

   · 

  2 min read
• Drug Development

  Bristol-Myers Squibb Release: First Presentation Of Two-Year Overall Survival Data For Opdivo (Nivolumab) In Combination With Yervoy (Ipilimumab) Showed Superior Efficacy Versus Yervoy Alone In Advanced Melanoma

  April 18, 2016

   · 

  1 min read